Lilly Q3 Results - Q3 Top Pharma Company Earnings Reports

View Lilly's Q3 Earnings Report

FiercePharma says: Lilly posted $941.8 million in third-quarter net income, way up from last year's $465.6 million loss on charges. More impressively, however, the company managed to boost sales by 6.8 percent during a quarter when its rivals had a tough time on the revenue side.. Read more of our coverage here...

Highlights:

  • Higher volume drives revenue growth
  • Stronger dollar results in improved gross margin
  • Earnings per share increase to $.86 (reported) or $1.20 (pro forma non-GAAP)
  • Full-year 2009 EPS guidance range revised to $3.90 - $4.00 (reported) or $4.30 - $4.40 (pro forma non-GAAP)

Check out Lilly's current earnings estimates from CNN Money

Lilly's Website: http://www.lilly.com/

Lilly Q3 Results - Q3 Top Pharma Company Earnings Reports
Read more on

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.